Area 1

Inflammatory joint diseases (IJDs)

Team leader

Strategic objectives

Promotion of research into the most prevalent chronic forms of immune mediated inflammatory arthritis: rheumatoid arthritis (RA) and spondyloarthritis, including psoriatic arthritis.

Main lines of research

1. Prognostic factors in early arthritis

  • Prognostic factors (clinical and immunogenetic) in patients with recentonset rheumatoid arthritis.
  • Production of new synthetic citrullinated peptides for the design of immunoassays with diagnostic and prognostic value in recent-onset rheumatoid arthritis and palindromic rheumatism.
  • Effect of tobacco on the phenotype of recent-onset rheumatoid arthritis
  • Calprotectin in inflammatory arthropathies

2. Clinical and sonographic characterization of clinical remission

  • Definition and clinical characterization of subclinical “active synovitis”
  • Immunopathological and molecular characterization of subclinical “active synovitis”.
  • Search of biomarkers of clinical reactivation and radiographic progression.

3. Immunopathology of synovitis in chronic arthritis

  • Utility in pathogenesis, differential diagnosis and prognosis of rheumatoid arthritis and psoriatic arthritis.
  • Immunopathological changes induced by biological treatments. Mechanism of action of targeted therapies.
  • Synovial biomarkers useful to clinically classify early undifferentiated arthritis.

4. Genomics and Pharmacogenomics of chronic arthritis

  • Genetic susceptibility to rheumatoid arthritis and psoriatic arthritis: GWAS studies (IMID-Biobank)
  • Genetic biomarkers associated to biological therapy response in rheumatoid arthritis and psoriatic arthritis (IMID-Biobank)

5. Role of autoinflammatory genes in the clinical phenotype of chronic arthritis

  • MEFV gene mutations in the diagnosis and treatment of undifferentiated intermittent arthritis. Utility of the test in a clinical setting.

6. Clinical implications of Immunogenicity of biological drugs in chronic arthritis